A perspective on multi-target drugs for Alzheimer's disease

O Benek, J Korabecny, O Soukup - Trends in pharmacological sciences, 2020 - cell.com
Alzheimer's disease (AD) has a complex pathophysiology that includes aggregation of
pathological proteins, impaired neurotransmission, increased oxidative stress, or microglia …

Management of mild cognitive impairment (MCI): the need for national and international guidelines

S Kasper, C Bancher, A Eckert, H Förstl… - The World Journal of …, 2020 - Taylor & Francis
Objectives: To review available evidence of pharmacological and non-pharmacological
treatment for MCI and analyse information and limitations in national and international …

Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial

NT Lautenschlager, KL Cox, L Flicker, JK Foster… - Jama, 2008 - jamanetwork.com
Context Many observational studies have shown that physical activity reduces the risk of
cognitive decline; however, evidence from randomized trials is lacking. Objective To …

Non-pharmacological interventions for adults with mild cognitive impairment and early stage dementia: An updated scoping review

J Rodakowski, E Saghafi, MA Butters… - Molecular aspects of …, 2015 - Elsevier
The purpose of this scoping review was to examine the science related to non-
pharmacological interventions designed to slow decline for older adults with Mild Cognitive …

Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease

R Leon, AG Garcia… - Medicinal research …, 2013 - Wiley Online Library
With 27 million cases worldwide documented in 2006, Alzheimer's disease (AD) constitutes
an overwhelming health, social, economic, and political problem to nations. Unless a new …

Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology

JT O'Brien, C Holmes, M Jones… - Journal of …, 2017 - journals.sagepub.com
The British Association for Psychopharmacology coordinated a meeting of experts to review
and revise its previous 2011 guidelines for clinical practice with anti-dementia drugs. As …

Treatment for mild cognitive impairment: systematic review

C Cooper, R Li, C Lyketsos… - The British Journal of …, 2013 - cambridge.org
Background More people are presenting with mild cognitive impairment (MCI), frequently a
precursor to dementia, but we do not know how to reduce deterioration. Aims To …

[HTML][HTML] Acetylcholine bidirectionally regulates learning and memory

Q Huang, C Liao, F Ge, J Ao, T Liu - Journal of Neurorestoratology, 2022 - Elsevier
Acetylcholine (ACh) is one of the most important neurotransmitters in the central cholinergic
system; it specifically binds to muscarinic and nicotinic receptors and is degraded by …

Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials

R Raschetti, E Albanese, N Vanacore… - PLoS medicine, 2007 - journals.plos.org
Background Mild cognitive impairment (MCI) refers to a transitional zone between normal
ageing and dementia. Despite the uncertainty regarding the definition of MCI as a clinical …

Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis

AC Tricco, C Soobiah, S Berliner, JM Ho, CH Ng… - Cmaj, 2013 - Can Med Assoc
Background: Cognitive enhancers, including cholinesterase inhibitors and memantine, are
used to treat dementia, but their effectiveness for mild cognitive impairment is unclear. We …